⚙
AI-generated deep summary
by qwen3.7-flash, 2026-08-14
· read from full text
ⓘ
This study analyzed tissue samples from 243 patients with primary ovarian carcinoma to determine the frequency and prognostic significance of c-erbB-2 oncogene overexpression. Immunohistochemical analysis revealed that 19% of the tumors exhibited p185 protein overexpression, which varied across different histological subtypes but showed no correlation with tumor stage or histological grade. Patients with positive staining for p185 experienced a significantly worse prognosis, with a median survival time of 19 months compared to 32 months for those with negative staining. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Abstract
In ovarian cancers, no valuable prognostic factors are available so far for predicting biological behaviour and clinical outcome. During the last years, overexpression of c-erbB-2-oncogene has been reported to be a prognostic factor in various human carcinomas. Its prognostic value in ovarian cancer is still a matter of controversy. The records and histological specimens of 243 patients with primary ovarian cancer were reviewed. Overexpression of c-erbB-2-oncogene encoded transmembrane protein p185 was determined immunohistochemically using polyclonal and monoclonal antibodies. Of 243 investigated tumours, 45 (19%) were positive. We examined the relationship between p185 and clinical stage, histological type, grading and prognosis. p185 overexpression differs within the histological subtypes of tumours. No correlation was found between p185 overexpression and stage or histological grade. The follow-up data demonstrate that patients with positive staining for p185 have a significantly worse prognosis (p = 0.001) than those with negative staining. These results suggest that overexpression of c-erbB-2 oncogene is associated with higher biological aggressiveness and unfavourable course of disease.
Full text
3,040 characters
· extracted from
oa-doi-fallback
· click to expand
DOI: 10.1055/s-2007-1026142
c-erbB-2-Onkogenüberexpression bei primären Ovarialkarzinomen: Häufigkeit und prognostische Bedeutung bei 243 Patientinnen
Overexpression of c-erbB-2-Oncogene in 243 Cases of Primary Ovarian Carcinoma: Frequency and Prognostic ValuePublication History
Publication Date:
18 March 2008 (online)
Zusammenfassung
Für das Ovarialkarzinom gibt es bislang keine Prognosefaktoren, die die Tumorbiologie und den Krankheitsverlauf hinreichend erfassen. In den letzten Jahren wurde über die prognostische Bedeutung der Amplifikation respektive Überexpression des Onkogens c-erbB-2 bei verschiedenen humanen Karzinomen berichtet, wobei die Bedeutung für das Ovarialkarzinom bis dato unterschiedlich bewertet und kontrovers diskutiert wurde. In der vorliegenden Studie wurde das Karzinomgewebe von 243 Patientinnen, die wegen eines primären Ovarialkarzinoms in der Zeit zwischen 1982 und 1991 in der UFK Göttingen onkologisch behandelt wurden, untersucht und die Überexpression des c-erbB-2-codierten Transmembranproteins immunhistochemisch bestimmt. In 19% (45 Fälle) der 243 analysierten Karzinome ließ sich eine p185-Überexpression nachweisen. Der prozentuale Anteil p185-positiver Befunde variierte innerhalb der verschiedenen histologischen Typen. Eine Korrelation zum Tumorstadium und den histologischen Differenzierungsgraden konnte nicht nachgewiesen werden. Patientinnen mit p185-positiven Tumoren hatten eine signifikant schlechtere Prognose (p = 0,001) mit einer medianen Überlebenszeit von 19 Monaten im Vergleich zu 32 Monaten für p185-negative Tumoren. Die vorliegenden Resultate erlauben die Schlußfolgerung, daß die Überexpression des Onkogens c-erbB-2 beim Ovarialkarzinom ein Kollektiv mit besonders ungünstiger Tumorbiologie und einer signifikant schlechteren Prognose charakterisiert.
Abstract
In ovarian cancers, no valuable prognostic factors are available so far for predicting biological behaviour and clinical outcome. During the last years, overexpression of c-erbB-2-oncogene has been reported to be a prognostic factor in various human carcinomas. Its prognostic value in ovarian cancer is still a matter of controversy. The records and histological specimens of 243 patients with primary ovarian cancer were reviewed. Overexpression of c-erbB-2-oncogene encoded transmembrane protein p185 was determined immunohistochemically using polyclonal and monoclonal antibodies. Of 243 investigated tumours, 45 (19%) were positive. We examined the relationship between p185 and clinical stage, histological type, grading and prognosis. p185 overexpression differs within the histological subtypes of tumours. No correlation was found between p185 overexpression and stage or histological grade. The followup data demonstrate that patients with positive staining for p185 have a significantly worse prognosis (p = 0,001) than those with negative staining. These results suggest that overexpression of c-erbB-2 oncogene is associated with higher biological aggressiveness and unfavourable course of disease.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.